

**Peginterferon Alfa-2b Redipen Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

---

**Section 1: Identification**

Product name : Peginterferon Alfa-2b Redipen Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908  
Upper Hutt - New Zealand

Telephone : 908-740-4000

Emergency telephone number : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Telefax : 908-735-1496

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

---

**Section 2: Hazard identification****GHS Classification**

Reproductive toxicity : Category 1B

**GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn child.

Precautionary statements :

**Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P281 Use personal protective equipment as required.

**Response:**  
P308 + P313 IF exposed or concerned: Get medical advice/attention.

**Storage:**  
P405 Store locked up.

**Disposal:**  
P501 Dispose of contents/ container to an approved waste

## Peginterferon Alfa-2b Redipen Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

disposal plant.

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.  
 Contact with dust can cause mechanical irritation or drying of the skin.  
 May form explosive dust-air mixture during processing, handling or other means.

### Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Peginterferon Alfa-2b	215647-85-1	$\geq 0.3$ - $< 1$

### Section 4: First-aid measures

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: May damage fertility. May damage the unborn child. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

### Section 5: Fire-fighting measures

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

## Peginterferon Alfa-2b Redipen Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

---

- potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

### Section 6: Accidental release measures

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
- 

### Section 7: Handling and storage

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety

## Peginterferon Alfa-2b Redipen Formulation

Version 5.2      Revision Date: 16.10.2020      SDS Number: 19441-00016      Date of last issue: 13.09.2019  
 Date of first issue: 07.10.2014

- practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.
- Conditions for safe storage : Keep in properly labelled containers.  
 Store locked up.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

### Section 8: Exposure controls/personal protection

#### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Peginterferon Alfa-2b	215647-85-1	TWA (inhalable fraction)	0.2 µg/m <sup>3</sup> (OEB 5)	Internal

- Engineering measures** : Minimize workplace exposure concentrations.  
 Apply measures to prevent dust explosions.  
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).  
 If sufficient ventilation is unavailable, use with local exhaust ventilation.

#### Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to

**Peginterferon Alfa-2b Redipen Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

Eye protection	:	chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Skin and body protection	:	Wear the following personal protective equipment: Safety goggles Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

**Section 9: Physical and chemical properties**

Appearance	:	powder
Colour	:	off-white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Solubility(ies) Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available

**Peginterferon Alfa-2b Redipen Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

---

Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

---

**Section 10: Stability and reactivity**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

**Acute toxicity**

Not classified based on available information.

**Components:****Peginterferon Alfa-2b:**

Acute toxicity (other routes of administration)	:	LD50 (Rat): > 20.1 mg/kg Application Route: Intravenous
---	---	--

LD50 (Monkey): > 9.8 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Peginterferon Alfa-2b:**

Species	:	Rabbit
Result	:	Mild skin irritation

**Peginterferon Alfa-2b Redipen Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

---

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Peginterferon Alfa-2b:**

Species	:	Rabbit
Result	:	Mild eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Peginterferon Alfa-2b:**

Genotoxicity in vitro	:	Test Type: reverse mutation assay Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: negative
Genotoxicity in vivo	:	Test Type: In vivo micronucleus test Species: Mouse Result: negative

**Carcinogenicity**

Not classified based on available information.

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Components:****Peginterferon Alfa-2b:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Monkey, female Application Route: Subcutaneous Dose: 0.35 milligram per kilogram Symptoms: Effect on estrous cycle
Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on development, based on animal experiments., Clear evidence of adverse effects on

**Peginterferon Alfa-2b Redipen Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

---

sexual function and fertility, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Components:****Peginterferon Alfa-2b:**

Target Organs	:	Gastrointestinal tract, Immune system, Cardio-vascular system, Endocrine system, Central nervous system, Liver, Respiratory Tract, Eye
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Peginterferon Alfa-2b:**

Species	:	Mouse
NOAEL	:	0.0038 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	9 d

Species	:	Rat
NOAEL	:	0.0042 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	30 d

Species	:	Monkey
LOAEL	:	0.12 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	30 d
Target Organs	:	Blood, Bone marrow, Immune system

Species	:	Monkey
NOAEL	:	0.015 mg/kg
LOAEL	:	0.077 mg/kg
Exposure time	:	3 Months
Target Organs	:	Respiratory Tract, Cardio-vascular system, Central nervous system, Bone marrow

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Peginterferon Alfa-2b:**

Inhalation	:	Symptoms: flu-like symptoms, Gastrointestinal disturbance, mental depression, tingling
------------	---	--



**Peginterferon Alfa-2b Redipen Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

---

**Section 12: Ecological information****Ecotoxicity****Components:****Peginterferon Alfa-2b:****Ecotoxicology Assessment**

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

**Persistence and degradability****Components:****Peginterferon Alfa-2b:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 63 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

**Bioaccumulative potential**

No data available

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**Section 13: Disposal considerations****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**Section 14: Transport information****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Peginterferon Alfa-2b Redipen Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****NZS 5433**

Not regulated as a dangerous good

**Section 15: Regulatory information****Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

not allocated

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**Section 16: Other information****Further information**Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect

**Peginterferon Alfa-2b Redipen Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
5.2	16.10.2020	19441-00016	Date of first issue: 07.10.2014

---

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN